Multiple enzymes in cholesterol biosynthesis

The term "Multiple enzymes in cholesterol biosynthesis" encompasses all enzymes participating in the endogenous synthesis of cholesterol from acetyl-CoA, including but not limited to HMG-CoA synthase, HMG-CoA reductase (the primary regulatory and drug target enzyme), mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, squalene synthase, squalene monooxygenase, lanosterol synthase, and others[3][4][1]. Each enzyme catalyzes a specific conversion step, and dysregulation or inherited deficiency of any component can lead to disease. The pathway is a major therapeutic target for managing high cholesterol and atherosclerosis, with statins exemplifying pathway inhibition at the HMG-CoA reductase step[2][4]. Other enzymes, such as ACATs involved in cholesterol storage and transport, are being pursued in metabolic and neurodegenerative disease contexts[1]. Since this is not a specific molecular entity, precision medicine and drug discovery efforts focus on individual enzymes rather than the group as a whole.

Other names

Cholesterol biosynthesis enzymesCholesterol synthesis enzymesSterol biosynthetic enzymes

Enzyme inhibition (most therapeutics block catalytic activity of rate-limiting or pathway enzymes)[1][2][4]; Feedback regulation (drugs may alter upstream or downstream cholesterol levels, thus affecting endogenous feedback loops)